Please use this identifier to cite or link to this item:
|Title:||THE ROLE OF TREFOIL FACTOR 3 IN MEDIATING RESISTANCE TOWARDS HER2-TARGETED DRUGS IN BREAST CANCER||Authors:||CHONG QING YUN||Keywords:||Trefoil Factor 3, HER2, Trastuzumab, Estrogen receptor, Breast cancer, Drug resistance||Issue Date:||19-Aug-2016||Citation:||CHONG QING YUN (2016-08-19). THE ROLE OF TREFOIL FACTOR 3 IN MEDIATING RESISTANCE TOWARDS HER2-TARGETED DRUGS IN BREAST CANCER. ScholarBank@NUS Repository.||Abstract:||The HER2-estrogen receptor crosstalk contributes to therapeutic resistance in HER2+/ER+ breast cancer. TFF3 is a crucial oncogene and mediator of anti-estrogen resistance in breast cancer. Here, the cross-regulation between HER2 and estrogen-responsive TFF3, and the functional role of TFF3 in trastuzumab resistant HER2+/ER+ breast cancer were investigated. We found that HER2 negatively regulates its own signaling through transcriptional repression of TFF3, while trastuzumab inhibition of HER2 increases TFF3 to compensate for loss of HER2 signaling. In trastuzumab resistant HER2+/ER+ breast cancer cells, TFF3 was markedly upregulated with a corresponding decrease in HER signaling. The inhibition of TFF3 decreased the survival and growth advantage of these resistant cells without re-sensitization to trastuzumab, indicating a shift in oncogene addiction from HER2 to TFF3. Furthermore, TFF3 inhibition abrogated the enhanced cancer stem cell-like behavior in these trastuzumab resistant cells. Taken together, TFF3 is a potential biomarker and therapeutic target in trastuzumab resistant HER2+/ER+ breast cancer.||URI:||http://scholarbank.nus.edu.sg/handle/10635/135089|
|Appears in Collections:||Ph.D Theses (Open)|
Show full item record
Files in This Item:
|ChongQY.pdf||4.54 MB||Adobe PDF|
checked on Apr 21, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.